$QTTB News

Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of Response

Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29

Q32 Bio: Durable Hair Regrowth Remains The Goal

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology Congress

Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio: The Efficacy Is Modest, The Valuation Is Not

Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio Q2 EPS $(0.44) Beats $(0.54) Estimate

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

HC Wainwright & Co. Maintains Buy on Q32 Bio, Raises Price Target to $36

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

Q32 Bio Files Prospectus For Offer And Resale Of 6.875M Shares By Selling Stockholders